Twist Bioscience Corporation (TWST)
NASDAQ: TWST · Real-Time Price · USD
173.45
+13.60 (8.51%)
At close: Oct 28, 2026, 4:00 PM EDT
169.92
-3.53 (-2.04%)
Pre-market: Oct 29, 2026, 7:16 AM EDT
Twist Bioscience Revenue
Twist Bioscience had revenue of $118.38M in the quarter ending June 30, 2026, with 23.24% growth. This brings the company's total for the last twelve months to $431.80M, up 19.19% year-over-year. In the fiscal year ending September 30, 2025, Twist Bioscience had annual revenue of $376.57M with 20.32% growth. That makes Twist Bioscience the 12,096th largest company in the world by revenue and 2,382nd in the United States.
Revenue (ttm)
$431.80M
Revenue Growth
+19.19%
P/S Ratio
25.19
Revenue / Employee
$441,060
Employees
979
Market Cap
10.88B
Revenue by Geography
- Americas 225.58M 59.9%
- Europe, Middle East and Africa (EMEA) 124.24M 33.0%
- Asia Pacific (APAC) 26.75M 7.1%
Fiscal year ended Sep 30, 2025 See the full Twist Bioscience breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 376.57M | 63.60M | 20.32% |
| Sep 30, 2024 | 312.97M | 67.87M | 27.69% |
| Sep 30, 2023 | 245.11M | 41.54M | 20.41% |
| Sep 30, 2022 | 203.57M | 71.23M | 53.83% |
| Sep 30, 2021 | 132.33M | 42.23M | 46.87% |
| Sep 30, 2020 | 90.10M | 35.72M | 65.67% |
| Sep 30, 2019 | 54.39M | 28.96M | 113.89% |
| Sep 30, 2018 | 25.43M | 14.66M | 136.16% |
| Sep 30, 2017 | 10.77M | 8.50M | 374.53% |
| Sep 30, 2016 | 2.27M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Madrigal Pharmaceuticals | 1.28B |
| Caris Life Sciences | 989.61M |
| Corcept Therapeutics | 830.81M |
| Arrowhead Pharmaceuticals | 669.50M |
| Krystal Biotech | 440.48M |
| Protagonist Therapeutics | 281.99M |
| ImmunityBio | 165.79M |
| Kymera Therapeutics | 105.00M |
TWST News
- 23 hours ago - Twist Bioscience expands portfolio with Twist Express Screening Antibodies - TheFly
- 23 hours ago - Twist Bioscience expands portfolio with Twist Express Screening Antibodies - TheFly
- 23 hours ago - Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodies - Business Wire
- 2 days ago - Twist Bioscience to Report Fiscal 2026 Fourth Quarter and Full Year Financial Results on Thursday, November 12, 2026 - Business Wire
- 14 days ago - How to Invest in AI Drug Discovery - ETF Trends
- 15 days ago - Twist Bioscience price target raised to $190 from $115 at TD Cowen - TheFly
- 17 days ago - Twist Bioscience price target raised to $205 from $120 at Canaccord - TheFly
- 21 days ago - Twist Bioscience initiated with a Hold at Jefferies - TheFly